Evaluation of increasing doses of gemfibrozil in hyperlipoproteinaemia

Proc R Soc Med. 1976;69 Suppl 2(Suppl 2):71-5.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Alkaline Phosphatase / blood
  • Aspartate Aminotransferases / blood
  • Cholesterol / blood
  • Clinical Trials as Topic
  • Creatine Kinase / blood
  • Humans
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / enzymology
  • Hypolipidemic Agents / administration & dosage*
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use
  • Middle Aged
  • Placebos
  • Time Factors
  • Triglycerides / blood
  • Valerates / administration & dosage*
  • Valerates / adverse effects
  • Valerates / therapeutic use
  • Xylenes / administration & dosage*
  • Xylenes / adverse effects
  • Xylenes / therapeutic use

Substances

  • Hypolipidemic Agents
  • Placebos
  • Triglycerides
  • Valerates
  • Xylenes
  • Cholesterol
  • Aspartate Aminotransferases
  • Creatine Kinase
  • Alkaline Phosphatase